



G Medical Innovations Holdings Ltd
ARBN 617 204 743

ASX Announcement

20 August 2020

Additional information on Nasdaq listing

Medical device, telehealth and medical services Company **G Medical Innovations Holdings Ltd (G Medical or the Company)** (ASX: GMV) wishes to provide shareholders with additional information on its formal application for the removal of the Company's fully paid ordinary shares (**Shares**) from the official list of the Australian Securities Exchange (**ASX**) (**Official List**) pursuant to ASX Listing Rule 17.11 and proposed listing on the Nasdaq Global stock exchange (**Nasdaq**) during Q4 2020 (refer ASX filing dated 13 August 2020).

Following a number of shareholder enquiries, the Company wishes to clarify that, in the event shareholders approve the removal of the Company from the Official List of ASX and the delisting is effectuated, there will not be "a very short period of privatisation" and shareholders who elect to retain their Shares will continue to hold their Shares after the removal of the Company from the Official List of the ASX and the Company will operate as an unlisted company until such time as the Nasdaq listing is effectuated.

If shareholder approval for the delisting is obtained, following its removal from the Official List of the ASX, G Medical will enter a brief period as an unlisted company to finalise the offer price in respect to its Nasdaq listing without being limited by the pricing restrictions under ASX Listing Rules, conduct a bookbuild, secure firm commitments whilst avoiding any impact of real time trading of the Company's securities on the ASX and seek to enter into proposed underwriting agreements.

During this period, the Company's Shares will continue to be held by G Medical's share registry, Automic Group (www.automicgroup.com.au). Shareholders can login in and manage their portfolio at any time with the Company's share registry via its website. The contact details for the share registry are also available on G Medical's website (www.gmedinnovations.com).

G Medical has confidentially filed a draft prospectus with the U.S. Securities and Exchange Commission. The Company, together with its advisors and underwriters, is working to finalise the prospectus in the coming weeks.

G Medical anticipates that listing on the Nasdaq will provide greater exposure to a larger market than the ASX, with a deeper understanding of telehealth and medical technology companies, and therefore the Company believes that delisting from the ASX is in the Company's best interest. In compliance with U.S. securities laws, shareholders can refer to the Nasdaq Initial Listing Guide at <https://listingcenter.nasdaq.com/assets/initialguide.pdf> for further details in respect to the Nasdaq listing process.

G Medical will continue to provide shareholders with updates on the progress of its Nasdaq listing and provide updates on material operational developments.

This press release does not constitute an offer to sell or the solicitation of an offer to buy securities, and shall not constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of that jurisdiction.

Ends

Authorised for release by Yacov Geva, Managing Director.

For more information, please contact:

Brendan De Kauwe
Director
Brendan@gmedinnovations.com

Henry Jordan
Six Degrees Investor Relations
Henry.jordan@sdir.com.au
+61 (0) 431 271 538

About G Medical Innovations:

G Medical (ASX: GMV) was founded in August 2014, aiming to be at the forefront of the digital health revolution, developing the next generation of mobile health (mHealth) technologies. The Company leverages the experience and expertise of its Board to deliver best-in-class solutions to address this global opportunity.

The Company specialises in innovative next generation mobile and telehealth solutions using its suite of proprietary devices and software solutions, as well as patient service operations, with a view to driving multiple and recurring revenue streams, across numerous verticals and territories.

For more information on G Medical, please visit www.gmedinnovations.com.

About G Medical products:

G Medical offers a suite of consumer and professional clinical-grade products (with regulatory approval) that are positioned to streamline healthcare services, improve remote access to medical data, reduce costs, improve quality of care, and make healthcare more personalized and precise. Currently the Company is focusing on two main verticals.

The 'Prizma' smartphone compatible medical device is one of two key products developed by G Medical and is aimed at everyday consumers focused on their medical health and wellbeing. The 'Prizma' allows consumers to turn their smartphone into a mobile medical monitor to measure a wide range of vital signs, with the added advantage that users are able to store their medical data in the cloud and share it with third parties such as healthcare professionals and family members.

G Medical also offers a professional real-time patient continuous monitoring solution, G Medical's Vital Signs Monitoring System (VSMS) and G Medical Patch (GMP). This modular solution measures a wide range of vital signs that are automatically presented in a call centre (IDTF) or a hospital setting. The GMP assists in diagnosing patient complaints and conditions remotely, from pre-hospitalisation, hospitalisation and through to post discharge homebased settings.